Background: Currently, there is no cure for epidermolysis bullosa (EB) but few studies have explored the role of aminoglycosides in promoting collagen 7 expression in recessive dystrophic EB (RDEB). Materials and Methods: Consecutive patients aged >1 year with a confirmed diagnosis of dystrophic EB (DEB) were advised to apply 0.1% w/w gentamicin cream in a collagen base (Derbriment G™) twice daily on a representative area on right lower limb (RLL) and paraffin gauze dressings on the corresponding opposite side on the left lower limb (LLL). Skin lesions were evaluated clinically during the 12-week treatment period at the end of which a repeat skin biopsy was sent for immunofluorescence antigen mapping (IFM). Results: Twelve patients with DEB were recruited but only eight completed the study and were analyzed. The mean fluorescence intensity (MFI) of the study cohort increased from 2765 ± 1732.07 (263-4845) at baseline to 5412.75 ± 3937.64 (2100-13536) at 12 weeks; a 95.75% (range 5.34%-775.14%) increase in the MFI of collagen 7 from baseline (P = 0.06). Among patients with a known termination codon mutation (n = 3), the percentage increase in MFI was greater among patients with known premature termination codon (PTC) mutations compared to those with unknown mutations. The clinical severity did not change significantly in terms of the mean number of blisters, erosions, and scarring during the study period. None of the parents reported any adverse effect. Conclusions: Topical gentamicin 0.1% w/w is a safe and effective way to promote the expression of COL7A1 in DEB patients, especially those carrying PTC mutations. Copyright:
Background: Currently, there is no cure for epidermolysis bullosa (EB) but few studies have explored the role of aminoglycosides in promoting collagen 7 expression in recessive dystrophic EB (RDEB). Materials and Methods: Consecutive patients aged >1 year with a confirmed diagnosis of dystrophic EB (DEB) were advised to apply 0.1% w/w gentamicin cream in a collagen base (Derbriment G™) twice daily on a representative area on right lower limb (RLL) and paraffin gauze dressings on the corresponding opposite side on the left lower limb (LLL). Skin lesions were evaluated clinically during the 12-week treatment period at the end of which a repeat skin biopsy was sent for immunofluorescence antigen mapping (IFM). Results: Twelve patients with DEB were recruited but only eight completed the study and were analyzed. The mean fluorescence intensity (MFI) of the study cohort increased from 2765 ± 1732.07 (263-4845) at baseline to 5412.75 ± 3937.64 (2100-13536) at 12 weeks; a 95.75% (range 5.34%-775.14%) increase in the MFI of collagen 7 from baseline (P = 0.06). Among patients with a known termination codon mutation (n = 3), the percentage increase in MFI was greater among patients with known premature termination codon (PTC) mutations compared to those with unknown mutations. The clinical severity did not change significantly in terms of the mean number of blisters, erosions, and scarring during the study period. None of the parents reported any adverse effect. Conclusions: Topical gentamicin 0.1% w/w is a safe and effective way to promote the expression of COL7A1 in DEB patients, especially those carrying PTC mutations. Copyright:
Authors: Jon Cogan; Jacqueline Weinstein; Xinyi Wang; Yingping Hou; Sabrina Martin; Andrew P South; David T Woodley; Mei Chen Journal: Mol Ther Date: 2014-07-23 Impact factor: 11.454
Authors: Vadim Lincoln; Jon Cogan; Yingping Hou; Michaela Hirsch; Michelle Hao; Vitali Alexeev; Michele De Luca; Laura De Rosa; Johann W Bauer; David T Woodley; Mei Chen Journal: Proc Natl Acad Sci U S A Date: 2018-06-26 Impact factor: 11.205
Authors: C Has; J W Bauer; C Bodemer; M C Bolling; L Bruckner-Tuderman; A Diem; J-D Fine; A Heagerty; A Hovnanian; M P Marinkovich; A E Martinez; J A McGrath; C Moss; D F Murrell; F Palisson; A Schwieger-Briel; E Sprecher; K Tamai; J Uitto; D T Woodley; G Zambruno; J E Mellerio Journal: Br J Dermatol Date: 2020-03-11 Impact factor: 9.302
Authors: David T Woodley; Jon Cogan; Yingping Hou; Chao Lyu; M Peter Marinkovich; Douglas Keene; Mei Chen Journal: J Clin Invest Date: 2017-07-10 Impact factor: 14.808
Authors: Ming Du; Julie R Jones; Jessica Lanier; Kim M Keeling; J Russell Lindsey; Albert Tousson; Zsuzsa Bebök; Jeffrey A Whitsett; Chitta R Dey; William H Colledge; Martin J Evans; Eric J Sorscher; David M Bedwell Journal: J Mol Med (Berl) Date: 2002-07-03 Impact factor: 4.599
Authors: Andrew Kwong; Jon Cogan; Yingping Hou; Richard Antaya; Michelle Hao; Gene Kim; Vadim Lincoln; Qiuyang Chen; David T Woodley; Mei Chen Journal: Mol Ther Date: 2020-03-17 Impact factor: 11.454